article thumbnail

Bromodomain Containing Protein 4 drugs in development, 2023

Pharmaceutical Technology

GlobalData’s report assesses the drugs in the Bromodomain Containing Protein 4 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein 130
article thumbnail

Chemical synthesis: containment challenges for HPAPI handling

Pharmaceutical Technology

These facilities are often multi-use CMO facilities, which combined with the use of HPAPIs, require stringent containment solutions to prevent cross-contamination. Solutions for Handling Nanogram Level Potent Products to Pass Containment Testing Criteria Webinar. Chemical synthesis solutions. Free Webinar. By ILC Dover. United Kingdom.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

UK MHRA publishes guidance on medicines containing valproate

Pharmaceutical Technology

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has published updated guidance on valproate-containing medicines.

Medicine 147
article thumbnail

Why choosing the right primary container is crucial

Bio Pharma Dive

New mRNA technology: identifying the right drug containment solution is more important than ever.

article thumbnail

What’s next for Container Closure Integrity Testing?

Pharmaceutical Technology

A vitally important assay used across various stages of drug development and manufacturing, container closure integrity testing (CCIT) involves evaluating packaging systems to determine their ability to protect the stability and sterility of pharmaceutical products. The post What’s next for Container Closure Integrity Testing?

article thumbnail

How API CMOs can improve containment capabilities without facility acquisition

Pharmaceutical Technology

According to GlobalData analysis, specialist small molecule API capabilities such as containment or controlled substances are driving large contract manufacturing organisations (CMOs) to acquire facilities. Flexible containment solutions for potent APIs. Partnering with containment experts.

article thumbnail

A winning combination: The benefits of micronization and containment in a single installation

Pharmaceutical Technology

This, coupled with small pharma companies being unable to acquire or access containment capabilities in-house, means that the demand for innovative specialized small molecule capabilities remains high. Premium specialized equipment is necessary because high containment facilities call for the separation of the operator from the product.